New pill targets Hard-to-Treat cancers with RAS mutations
NCT ID NCT07435038
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental oral drug, BPI-572270, in 120 adults with advanced solid tumors (lung, colorectal, or pancreatic cancer) that have specific RAS gene mutations. The trial has two phases: first to find a safe dose and check for side effects, then to see if the drug shrinks tumors. All participants have already tried standard treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BPI-572270 (oral tablet)
- What this could lead to
- If successful, this could lead to a new targeted treatment option for people with advanced cancers that have specific RAS mutations.
- What could go wrong
- This is an early-phase trial (Phase 1/2) with only 120 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Why are more younger adults getting colorectal cancer? a national study digs into the data
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a pill outsmart Tumors' defenses?
- Can a new immune drug outsmart Hard-to-Treat tumors?